Bio
Dr. Cornelia Dekker is a Pediatric Infectious Diseases physician who came to Stanford after a 12-year career in vaccine clinical development at Lederle Biologicals and Chiron Vaccines where she served as Vice President, Clinical Research and Medical Affairs. In this position, she was responsible for the clinical development of 18 vaccine candidates, including those for HSV, HIV, meningococcus A and C, adjuvanted influenza, acellular pertussis-DT, hepatitis A, hepatitis B, hepatitis C, H. influenza type b and CMV. During her tenure, Chiron’s clinical program included testing of a recombinantly produced HSV gD2/gB2 vaccine with MF59 adjuvant for the amelioration of established genital herpes infection and the prevention of genital herpes in high-risk adults, and the first influenza vaccine combined with the MF59 adjuvant that was licensed intially in Europe and South America and just recently also in the US.
Dr. Dekker joined the Stanford University School of Medicine faculty in the Division of Pediatric Infectious Diseases and was named Medical Director of the Stanford-LPCH Vaccine Program in 1999. She has served as the Stanford PI on NIH-sponsored Vaccine and Treatment Evaluation Unit subcontracts to study new vaccine candidates and on a CDC-sponsored Clinical Immunization Safety Assessment Center contract evaluating safety of licensed vaccines. She leads the Stanford Clinical Core for NIH-sponsored studies looking at the detailed immune responses to influenza vaccines in children compared with young and elderly adults that has expanded to investigate genetic factors by also studying responses of identical and fraternal twins. Dr. Dekker’s expertise in vaccines has been tapped by NIH to serve on several vaccine safety and data monitoring boards, and she currently is Chair of the HIV Vaccine Trial Network Safety Monitoring Board. On the National Vaccine Advisory Committee, she served on the Vaccine Safety Working Group and H1N1 Vaccine Safety Subgroup among others. In 2016, she was named Medical Director for the Stanford Clinical and Translational Research Unit.
